| Embryonic stem cell–specific microRNAs promote induced pluripotency RL Judson, JE Babiarz, M Venere, R Blelloch Nature biotechnology 27 (5), 459-461, 2009 | 957 | 2009 |
| Opposing microRNA families regulate self-renewal in mouse embryonic stem cells C Melton, RL Judson, R Blelloch Nature 463 (7281), 621-626, 2010 | 878 | 2010 |
| Multiple targets of miR-302 and miR-372 promote reprogramming of human fibroblasts to induced pluripotent stem cells D Subramanyam, S Lamouille, RL Judson, JY Liu, N Bucay, R Derynck, ... Nature biotechnology 29 (5), 443-448, 2011 | 725 | 2011 |
| miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastoma A Swarbrick, SL Woods, A Shaw, A Balakrishnan, Y Phua, A Nguyen, ... Nature medicine 16 (10), 1134-1140, 2010 | 245 | 2010 |
| Genomic and transcriptomic analysis reveals incremental disruption of key signaling pathways during melanoma evolution AH Shain, NM Joseph, R Yu, J Benhamida, S Liu, T Prow, B Ruben, ... Cancer cell 34 (1), 45-55. e4, 2018 | 211 | 2018 |
| Quantitative phase imaging: recent advances and expanding potential in biomedicine TL Nguyen, S Pradeep, RL Judson-Torres, J Reed, MA Teitell, TA Zangle ACS nano 16 (8), 11516-11544, 2022 | 172 | 2022 |
| Bi-allelic loss of CDKN2A initiates melanoma invasion via BRN2 activation H Zeng, A Jorapur, AH Shain, UE Lang, R Torres, Y Zhang, AS McNeal, ... Cancer cell 34 (1), 56-68. e9, 2018 | 136 | 2018 |
| Combined activation of MAP kinase pathway and β-catenin signaling cause deep penetrating nevi I Yeh, UE Lang, E Durieux, MK Tee, A Jorapur, AH Shain, V Haddad, ... Nature communications 8 (1), 644, 2017 | 135 | 2017 |
| The genomic landscapes of individual melanocytes from human skin J Tang, E Fewings, D Chang, H Zeng, S Liu, A Jorapur, RL Belote, ... Nature 586 (7830), 600-605, 2020 | 117 | 2020 |
| Human melanocyte development and melanoma dedifferentiation at single-cell resolution RL Belote, D Le, A Maynard, UE Lang, A Sinclair, BK Lohman, ... Nature Cell Biology 23 (9), 1035-1047, 2021 | 101 | 2021 |
| Two miRNA clusters reveal alternative paths in late-stage reprogramming RJ Parchem, J Ye, RL Judson, MF LaRussa, R Krishnakumar, A Blelloch, ... Cell stem cell 14 (5), 617-631, 2014 | 101 | 2014 |
| microRNA control of mouse and human pluripotent stem cell behavior TS Greve, RL Judson, R Blelloch Annual review of cell and developmental biology 29 (1), 213-239, 2013 | 101 | 2013 |
| Prognostic gene expression profiling in cutaneous melanoma: identifying the knowledge gaps and assessing the clinical benefit D Grossman, N Okwundu, EK Bartlett, MA Marchetti, M Othus, DG Coit, ... JAMA dermatology 156 (9), 1004-1011, 2020 | 91 | 2020 |
| Genetic heterogeneity of BRAF fusion kinases in melanoma affects drug responses T Botton, E Talevich, VK Mishra, T Zhang, AH Shain, C Berquet, ... Cell Reports 29 (3), 573-588. e7, 2019 | 87 | 2019 |
| High accuracy label-free classification of single-cell kinetic states from holographic cytometry of human melanoma cells M Hejna, A Jorapur, JS Song, RL Judson Scientific reports 7 (1), 11943, 2017 | 73 | 2017 |
| MicroRNA-based discovery of barriers to dedifferentiation of fibroblasts to pluripotent stem cells RL Judson, TS Greve, RJ Parchem, R Blelloch Nature structural & molecular biology 20 (10), 1227-1235, 2013 | 72 | 2013 |
| CDK1 inhibition targets the p53-NOXA-MCL1 axis, selectively kills embryonic stem cells, and prevents teratoma formation NE Huskey, T Guo, KJ Evason, O Momcilovic, D Pardo, KJ Creasman, ... Stem cell reports 4 (3), 374-389, 2015 | 70 | 2015 |
| Mucosal melanoma: pathological evolution, pathway dependency and targeted therapy Y Ma, R Xia, X Ma, RL Judson-Torres, H Zeng Frontiers in oncology 11, 702287, 2021 | 65 | 2021 |
| The genetic evolution of melanoma AH Shain, R Yu, I Yeh, J Benhamida, I Kovalyshyn, A Sriharan, E Talevich, ... Cancer Research 76 (14_Supplement), 2372-2372, 2016 | 55 | 2016 |
| Research techniques made simple: feature selection for biomarker discovery R Torres, RL Judson-Torres Journal of Investigative Dermatology 139 (10), 2068-2074. e1, 2019 | 50 | 2019 |
